NRx Pharmaceuticals, Inc. (NRXP) Tops Q3 EPS by 4c

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on NRx Pharmaceuticals, Inc. (NRXP) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Equirus Starts JSW Energy Ltd (JSW:IN) at Long (1)